EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Baseline fasting insulin is associated with early height gain during recombinant human growth hormone therapy in children with idiopathic short stature

Yuanyuan Ju, Dingding Wang, Wei Song

Frontiers in Pediatrics · 16.11.2026 · 14

DOI: 10.3389/fped.2026.1951143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pediatrics, online erschienen am 16.11.2026. Verfasst von Yuanyuan Ju und 2 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fasting insulin modulates growth hormone (GH) signaling and insulin-like growth factor 1 (IGF-1) synthesis, but its relation to early height response to recombinant human GH (rhGH) therapy is unclear. We examined this in children with idiopathic short stature (ISS).

Methods

This single-center retrospective cohort study reviewed records of children aged 3–14 years who started rhGH monotherapy for ISS at a tertiary pediatric endocrinology center between December 2018 and December 2024. Children with another identifiable cause of short stature, obesity, diabetes, uncontrolled hypothyroidism, Turner syndrome or concurrent gonadotropin-releasing hormone agonist therapy were excluded. The primary outcome was the change in height standard deviation score (SDS) from baseline to 3 months, and the secondary outcomes were the 3-month height gain and the change in height SDS from baseline to 6 months. Baseline fasting insulin and the homeostatic model assessment of insulin resistance (HOMA-IR) were related to the outcomes by Spearman correlation and by linear regression adjusted for age, sex, baseline height SDS and baseline IGF-1 SDS, with a sensitivity model adding rhGH dose and Bonferroni correction.

Results

Of 224 eligible children, 169 with complete baseline and 3-month data formed the primary analysis set, and 210 with 6-month data were analyzed for the 6-month outcome. Baseline fasting insulin correlated with the 3-month change in height SDS [Spearman correlation coefficient (rs) = 0.667], the 3-month height gain (rs = 0.331) and the 6-month change in height SDS (rs = 0.500), all p < 0.0001 and significant after Bonferroni correction. In multivariable regression (coefficient of determination R 2 = 0.209), each 1 μ U/mL higher fasting insulin was associated with a 0.034 greater 3-month change in height SDS (95% confidence interval [CI] 0.018–0.050, p < 0.0001), and the association persisted after adjustment for rhGH dose (0.036, 95% CI 0.020–0.052).

Conclusions

Baseline fasting insulin was associated with early height SDS gain during rhGH therapy in children with ISS after adjustment for age, sex, baseline height SDS and IGF-1 SDS, although residual confounding, particularly by pubertal status, cannot be excluded. These retrospective, unvalidated findings are hypothesis-generating and do not support using fasting insulin to guide rhGH dosing.

Förderung

  • Natural Science Foundation of Shandong Province

Zitieren

APA

Ju, Y., Wang, D., & Song, W. (2026). Baseline fasting insulin is associated with early height gain during recombinant human growth hormone therapy in children with idiopathic short stature. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1951143

Vancouver

Ju Y, Wang D, Song W. Baseline fasting insulin is associated with early height gain during recombinant human growth hormone therapy in children with idiopathic short stature. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1951143

BibTeX
@article{Ju2026,
  author = {Ju, Yuanyuan and Wang, Dingding and Song, Wei},
  title = {Baseline fasting insulin is associated with early height gain during recombinant human growth hormone therapy in children with idiopathic short stature},
  journal = {Frontiers in Pediatrics},
  year = {2026},
  volume = {14},
  doi = {10.3389/fped.2026.1951143}
}
Kostenlos starten →